Although interleukin 1 (IL-1) induces expression of the transcription factor IRF1 (interferon-regulatory factor 1), the roles of IRF1 in immune and inflammatory responses and mechanisms of its activation remain elusive. Here we found that IRF1 was essential for IL-1-induced expression of the chemokines CXCL10 and CCL5, which recruit mononuclear cells into sites of sterile inflammation. Newly synthesized IRF1 acquired Lys63 (K63)-linked polyubiquitination mediated by the apoptosis inhibitor cIAP2 that was enhanced by the bioactive lipid S1P. In response to IL-1, cIAP2 and the sphingosine kinase SphK1 (the enzyme that generates S1P) formed a complex with IRF1, which led to its activation. Thus, IL-1 triggered a hitherto unknown signaling cascade that controlled the induction of IRF1-dependent genes that encode molecules important for sterile inflammation.
Interleukin 1 (IL-1) is a pleiotropic cytokine that regulates a broad range of both immune and inflammatory responses and has a pivotal role in autoinflammatory diseases 1 but does not have direct antiviral activity 2 . Accordingly, IL-1 induces the expression of various proinflammatory cytokines and chemokines but does not stimulate the production of substantial amounts of the type I interferons needed for the orchestration of antiviral responses. The inflammatory effects of IL-1 are mediated mainly by activation of the transcription factor NF-κB and mitogen-activated protein kinases (MAPKs) 3 . IL-1 initiates signaling after it binds to its receptor complex, IL-1R, which leads to recruitment of the cytosolic adaptor MyD88 via the Toll-IL-1R domain of IL-1R 4 . MyD88 recruits the kinases IRAK4 and IRAK1, which results in the hyperphosphorylation of IRAK1 by IRAK4 (ref. 5 ). The E3 ubiquitin ligase TRAF6 (which contains a RING ligase domain that promotes ubiquitination) is then recruited and activated 6 . TRAF6 conjugates Lys63 (K63)-linked polyubiquitin chains to itself and to IRAK1, which allows recruitment of the kinase TAK1, the TAK1-binding proteins TAB2 and TAB3, and the linear ubiquitin assembly complex (LUBAC). In turn, LUBAC generates linear polyubiquitin chains that recruit the kinase IKK ('inhibitor of NF-κB kinase') complex 7 . Subsequently, TRAF6 decorates both IKKγ (a regulatory subunit of the IKK complex) and TAK1 with K63-linked polyubiquitin chains, which leads to the activation of NF-κB and MAPKs [8] [9] [10] [11] . In addition to that activation cascade that requires the RING domain of TRAF6, NF-κB can also be activated by the oligomerization of the MAPK kinase kinase MAP3K3, which is orchestrated by TRAF6 and requires its zinc-finger domain but not a functional RING domain 12 .
While Toll-like receptor (TLR) ligands and IL-1 both activate NF-κB and MAPKs, which are required for antiviral and inflammatory responses, the antiviral response is restricted to TLRs because of their ability to induce the production of type I interferons by activation of interferon-regulatory factors (IRFs) 13 . IRF3 and IRF7 are critical regulators of the production of type I interferon; nevertheless, both IRF1 and IRF5 also can induce type I interferons in TLR-and cell-specific ways 14, 15 . Although Irf1 −/− mice have normal serum concentrations of type I interferons 16 , IRF1 regulates the TLR9-induced production of interferon-β (IFN-β) in conventional dendritic cells 14 , low expression of IFN-β induced by tumor-necrosis factor (TNF) 17 , expression of nitric oxide synthase and the p35 subunit of IL-12 in macrophages 18 , and priming of chromatin in IFN-γ-stimulated macrophages 19 . IRF1 also controls the recruitment of macrophages by TNF-activated endothelial cells 20 , immune responses to infection with West Nile virus 21 and the pathogenesis of autoimmune diseases 22 , including collagen-induced arthritis and experimental autoimmune encephalomyelitis in mice.
Although expression of several IRFs is induced by both interferons and cytokines, activation of those IRFs requires the acquisition of A r t i c l e s post-transcriptional modifications, including K63-linked polyubiquitination and phosphorylation. TRAF6 serves as an E3 ubiquitin ligase for both IRF5 (ref. 15 ) and IRF7 (ref. 23) , and K63-linked polyubiquitination of IRF7 is a prerequisite for subsequent phosphorylation of IRF7 (ref. 23) . Expression of IRF1 is strongly induced by IFN-γ and it can be further activated by TLRs 24 . The mechanism of that activation is not known, but it involves the formation of a complex of IRF1 with MyD88 (ref. 24) . IL-1 also induces expression of IRF1, and MyD88 is an adaptor for IL-1 signaling.
In this study, we found that IRF1 controlled the expression of 'delayed' IL-1-responsive genes that require prior synthesis of IRF1 protein, including those that encode the chemokines CXCL10 and CCL5, which are important for the recruitment of mononuclear cells into sites of sterile inflammation. In response to IL-1, newly synthesized IRF1 underwent K63-linked polyubiquitination by the apoptosis inhibitor cIAP2; this required the bioactive sphingolipid mediator S1P, which directly bound to and enhanced the E3 ubiquitin ligase activity of cIAP2. Thus, in addition to triggering well-documented NF-κB-activation pathways, IL-1 triggered a previously undefined signaling pathway that regulated a set of IRF1-responsive genes that encode molecules important for sterile inflammation.
RESULTS

IL-1 induces expression of CXCL10 and CCL5 via IRF1
IL-1 orchestrates immune and inflammatory responses by regulating expression of its target genes in many different cell types by various molecular mechanisms. In human astrocytes, as has been reported for other cell types, IL-1 rapidly induced the expression of genes controlled by the activation of NF-κB and MAPKs, including those that encode IL-6, IL-8 and CCL4 (Supplementary Fig. 1a ). In addition, in both human astrocytes and mouse astrocytes, IL-1 induced the expression of CXCL10 mRNA and CCL5 mRNA ( Fig. 1a,b and Supplementary Fig. 1b ); the promoters of the genes encoding those mRNAs contain interferon-stimulated response elements that can bind either IRFs or the ISGF3 complex (which contains the type I interferon effectors STAT1 and STAT2, and IRF9) 17, 25 . IL-1 rapidly induced the expression of IRF1 mRNA ( Fig. 1a-c) and IRF1 protein and its subsequent accumulation in the nucleus (Fig. 1a) . The absence of IRF1 in mouse embryonic fibroblasts (MEFs) resulted in almost complete elimination of the induction of CXCL10 mRNA and CCL5 mRNA by IL-1 observed in wild-type MEFs, whereas expression of IL-6 mRNA was diminished to a lesser extent ( Fig. 1c) . We next investigated whether deficiency in IRF1 also impaired production of those chemokines in vivo. Intraperitoneal administration of IL-1 to wild-type mice resulted in much higher concentrations of CXCL10 and CCL5 in the serum, while those responses to IL-1 were almost completely ablated in Irf1 −/− mice (Fig. 1d) . In contrast to the expression of CXCL10 and CCL5, IL-1-induced IL-6 expression was similar in wild-type and Irf1 −/− mice ( Fig. 1d) . We further examined the specific requirement for IRF1 in vivo through studies of Stat1 −/− mice and Irf3 −/− Irf7 −/− double-knockout mice. Although IRF3 and IRF7 regulate the expression of CXCL10 and CCL5 upon TLR activation 26, 27 and their expression also can be induced by the STAT1-STAT2-IRF9 heterotrimer 17, 25 , the concentration of CXCL10 and CCL5 in the serum of IL-1-treated Irf3 −/− Irf7 −/− mice and Stat1 −/− mice was similar to that of their wild-type counterparts (Fig. 1e) . Thus, IRF1 was essential for IL-1-induced expression of CXCL10 and CCL5 in cells and in vivo, but IRF3 and IRF7 were not.
IRF1 regulates the recruitment of mononuclear cells
Since a deficiency of IRF1 results in autoimmune diseases 22 that are thought to be caused by dysfunction of T cells 28 WT Irf3 npg the importance of IRF1 activation through use of the turpentine model of irritant-induced sterile inflammation that is IL-1 dependent 29 . Expression of CXCL10 mRNA and CCL5 mRNA was induced substantially at the sites of turpentine injection in wild-type mice but was much lower in their Irf1 −/− counterparts (92% and 97%, respectively; Fig. 2a ). The expression of IRF1-independent mRNAs that encode the cytokines CCL2, IL-1 and IL-6 was also affected in Irf1 −/− mice but to a lesser extent (48%, 78% and 79%, respectively; Fig. 2a ). Although subsequent infiltration of inflammatory cells into the irritated skin area was evident in both wild-type and Irf1 −/− mice, the infiltration of CD8 + T cells was attenuated in Irf1 −/− mice ( Fig. 2b) . There was also a trend that suggested that infiltration of CD4 + T cells, monocytes (CD11b + Gr-1 − ) and bone marrow-derived immature myeloid cells (CD11b + Gr-1 + ) was attenuated in Irf1 −/− mice ( Fig. 2c and Supplementary Fig. 2a,b) . The diminished infiltration of those cells was probably a result of lower local expression of CXCL10 and CCL5 in Irf1 −/− mice ( Fig. 2a ) and not the difference in the initial number of cells in subsets of the immune system. Although Irf1 −/− mice have considerably fewer CD8 + cells than do wild-type mice 30 , we found that Irf1 −/− and wild-type mice had similar numbers of CD4 + cells, monocytes and bone marrow-derived immature myeloid cells ( Supplementary Fig. 2d ). Collectively, these data suggested that IRF1-dependent expression of CXCL10 and CCL5 was required for the effective recruitment of mononuclear cells into sites of sterile inflammation.
IL-1 induces K63-linked polyubiquitination of IRF1
IRF3 is phosphorylated by the IKKε-TBK1 complex 31 , whereas IRF1 requires IKKα for its activation by TLR9 (ref. 14) . In addition to undergoing phosphorylation, IRF3, IRF5 and IRF7 undergo K63linked polyubiquitination that is needed for their activation 15, 23, 32 , and that modification is a prerequisite for the phosphorylation of IRF7 (ref. 23 ). To determine whether activation of IRF1 by IL-1 also involves its K63-linked polyubiquitination, we coexpressed IRF1 and wild-type, K63-only or K48-only ubiquitin in HEK293 human embryonic kidney cells and stimulated the cells with IL-1. Indeed, IL-1 enhanced K63-linked polyubiquitination of IRF1, whereas K48linked polyubiquitination, which targets IRF1 for degradation, was not affected (Fig. 3a) . We also detected IL-1-induced K63-linked polyubiquitination of IRF1 with an antibody specific for K63-linked ubiquitin (Fig. 3b) . In searching for the E3 ubiquitin ligase that mediates IL-1-induced K63-linked polyubiquitination of IRF1, we focused on TRAF6, which is indispensable for IL-1-induced activation of NF-κB 6 . We also assessed cIAP1 and cIAP2 because expression of these E3 ligases is induced by NF-κB 33 , which is activated by IL-1. We included S1P in the in vitro ubiquitination reactions because S1P is a cofactor for the E3 ligase activity of TRAF2 that mediates K63-linked polyubiquitination of the signaling mediator RIP1 in response to signaling via TNF 34 . Although incubation of IRF1 with ubiquitin and the ubiquitin-activating enzymes E1 and E2 together with TRAF2, TRAF6 or cIAP1 did not produce polyubiquitinated IRF1 in vitro, cIAP2 effectively polyubiquitinated IRF1 in the presence of S1P ( Fig. 3c) . Moreover, S1P enhanced both total and K63-linked polyubiquitination of IRF1 but had no effect on K48-linked polyubiquitination of IRF1 ( Fig. 3d) . Furthermore, the stimulatory effect of S1P was specific, as other structurally related phospholipids, including dihydro-S1P, sphingosine, dihydro-sphingosine and lysophosphatidic acid, were ineffective at inducing K63-linked polyubiquitination of IRF1 ( Fig. 3e ).
Polyubiquitination of IRF1 was also evident in TNF-treated cells ( Fig. 3f) , which correlated with the reported activation of IRF1 by TNF 17 .
To identify sites of polyubiquitination, we generated IRF1 mutants with replacement of lysine with arginine ( Fig. 3g ) and assessed their ability to induce an IFN-β reporter gene. We found that wild-type IRF1 and three IRF1 mutants that contained Lys75, Lys78, Lys95 and Lys101 efficiently activated the reporter, and this was enhanced by IL-1 (Fig. 3h) . Wild-type IRF1 and the IRF1 mutant that contained Lys75, Lys78, Lys95 and Lys101 only also underwent K63-linked polyubiquitination, and their polyubiquitination was enhanced by IL-1 (Fig. 3i) . In contrast, an IRF1 mutant that lacked Lys75, Lys78, Lys95 and Lys101 did not undergo K63-linked polyubiquitinated and did not activate the reporter (Fig. 3h,i) , which suggested that at least one of those lysine residues (Lys75, Lys78, Lys95 or Lys101) was a site of polyubiquitination and was important for IRF1 function. IL-1 also efficiently promoted the ubiquitination of cIAP2 ( Fig. 3j,k) , which suggested activation of cIAP2. Together these results suggested that activation of IRF1 required K63-linked polyubiquitination and that this was mediated by cIAP2 in the presence of S1P.
IL-1 induces the formation of an IRF1 signaling complex
Thus far, cIAP2 and S1P have not been linked to IL-1-induced signaling or activation of IRFs by IL-1R or TLRs. For that reason, npg it was important to demonstrate that cIAP2 and the sphingosine kinase SphK1, one of the two isoenzymes able to produce S1P, can be recruited to the known IL-1-induced signaling complexes. Stimulation with IL-1 induced sustained phosphorylation of SphK1 at Ser225 (Fig. 4a) , which is known to enhance its enzymatic activity 35 . Accordingly, the amount of S1P doubled 2 h after stimulation of astrocytes with IL-1 (Fig. 4b) , which suggested that S1P was produced at the time that newly synthesized IRF1 was activated ( Fig. 1a) . We were also able to coimmunoprecipitate SphK1 and cIAP2, and that interaction was enhanced by IL-1 ( Fig. 4c,d) , which indicated that S1P produced by SphK1 was available to bind to cIAP2. Moreover, IL-1 enhanced the interaction of endogenous cIAP2 with SphK1 ( Fig. 4e) .
To understand mechanistic basis of the activation of cIAP2 by IL-1 signaling, we first investigated whether IL-1-activated TRAF6 recruits cIAP2. IL-1 promoted the interaction of TRAF6 and cIAP2 ( Fig. 4f-h) , in contrast to the constitutive cIAP2-TRAF2 interaction 36 ( Fig. 4g) , which suggested that cIAP2 was specifically recruited by IL-1-activated TRAF6. Thus, IL-1-induced activation of TRAF6 led to the recruitment of both cIAP2 and SphK1, and phosphorylation of SphK1, which can locally produce S1P. Moreover, IL-1 also stimulated the interaction of cIAP2 with IRF1 ( Fig. 4i) , which suggested that IRF1 was also recruited to that complex. These data suggested that IL-1 signaling recruited both SphK1 and cIAP2, which may be important for IRF1 activation.
SphK1 is needed for IL-1-induced chemokine expression
Since S1P was required for cIAP2-mediated K63-linked polyubiquitination of IRF1 in vitro ( Fig. 3c ) and SphK1 associated with cIAP2 ( Fig. 4c-e ), it was important to determine whether SphK1 was indispensable for IL-1-induced expression of CXCL10 and CCL5 in vitro and in vivo. SKI-1, a highly specific small-molecule inhibitor of SphK1 (ref. 37 ), abolished the IL-1-induced expression of CCL5 mRNA and diminished the IL-1-induced expression of CXCL10 mRNA by 50% in primary human astrocytes (Fig. 5a) . However, SKI-1 had no effect on basal or IL-1-induced expression of IRF1 mRNA or SphK1 mRNA (Fig. 5a) , which suggested that SphK1 activity was needed specifically for IL-1-induced expression of IRF1-dependent genes. SKI-1 also substantially decreased the concentration of CXCL10 and CCL5 in the serum of mice given IL-1 exogenously but had no effect on the concentration of IL-6, whose expression is not regulated by IRF1 (Fig. 5b) . Bottom, immunoblot analysis with anti-Flag (loading control). (j) Immunoassay of HEK293 cells expressing HA-tagged cIAP2 and stimulated as in a, followed by immunoprecipitation of cIAP2 with anti-HA and immunoblot analysis of ubiquitination with anti-ubiquitin. Bottom, immunoblot analysis with anti-HA (loading control). (k) Immunoassay of HEK293 cells expressing HA-tagged cIAP2 and stimulated for 0-120 min (above lanes) with IL-1, followed by immunoprecipitation as in j and immunoblot analysis with anti-HA. Data are representative of at least three experiments with similar results (a-f,h-k; error bars (h), s.d.) or three experiments (g).
A r t i c l e s
Thus, pharmacological inhibition of SphK1 specifically inhibited the IL-1-induced expression of IRF1-dependent genes in vitro and in vivo. We also determined whether IL-1-induced expression of CXCL10 and CCL5 was altered in Sphk1 −/− mice. Although SphK1 deficiency resulted in higher basal expression of mRNA encoding both IRF1dependent cytokines and IRF1-independent cytokines, it also diminished the IL-1-induced mRNA expression of CXCL10 and CCL5 but not of IL-6 ( Fig. 5c) . Thus, SphK1 and its enzymatic activity were critical for the IL-1-induced expression of CCL5 and CXCL10.
IL-1-induced chemokine expression requires cIAP2
Our in vitro ubiquitination data suggested that cIAP2 mediated K63-linked polyubiquitination of IRF1 in the presence of S1P, but cIAP1 did not (Fig. 3c) . Accordingly, IL-1-induced expression of CCL5 mRNA was completely abolished and that of CXCL10 mRNA was profoundly diminished in cIAP2-deficient (Birc3 −/− ) MEFs (Fig. 6a) . In contrast, IL-1-induced expression of NF-κB-dependent genes, including those encoding IRF1, CCL2 and CXCL9, was normal in Birc3 −/− MEFs (Fig. 6a) , in support of published reports that cIAP1 npg and cIAP2 are redundant for many biological functions, including their role in NF-κB activation 38 . To determine if cIAP2 was needed for IL-1-induced polyubiquitination of IRF1, we pretreated cells with SMAC, a mimetic of the caspase activator Smac that causes degradation of both cIAP1 and cIAP2 (ref. 39) . SMAC effectively blocked both basal and IL-1-induced polyubiquitination of IRF1 (Fig. 6b) . To confirm that cIAP2 mediated the polyubiquitination of IRF1, we analyzed the ubiquitination of IRF1 in wild-type and Birc3 −/− MEFs. Although IL-1 induced effective polyubiquitination of IRF1 in wild-type MEFs, it did not induce much polyubiquitination of IRF1 in Birc3 −/− MEFs (Fig. 6c) . These data suggested that cIAP2 mediated the polyubiquitination of IRF1, which activated IRF1 and IRF1-dependent gene expression, but cIAP1 did not do so.
S1P binds to cIAP2 and promotes polyubiquitination of IRF1
Published studies have shown that S1P binds to TRAF2 and promotes K63-linked polyubiquitination of RIP1 in response to TNF 34 . To assess whether S1P promotes the polyubiquitination of IRF1 by binding to cIAP2, we immunoprecipitated both IRF1 and cIAP2 and analyzed the binding of S1P to those molecules by liquid chromatographyelectrospray ionization-tandem mass spectrometry. S1P bound to cIAP2 but not to IRF1 (Fig. 7a) . In agreement with that, 32 P-labeled-S1P effectively bound to recombinant cIAP2, and that binding competed with unlabeled S1P but not other related lipids, including sphingosine and lysophosphatidic acid (Fig. 7b) . Molecular modeling of the binding of S1P to cIAP2 suggested that S1P binds to the groove present in the RING domain of cIAP2 (Fig. 7c) , and its binding could be stabilized further by the interaction of a positively charged region (containing Thr594 and Lys596) with the phosphate group of S1P (Supplementary Fig. 3a) . To assess those predictions, we generated a cIAP2 mutant with three substitutions (T594A, I595A and K596A) and assessed S1P binding and in vitro E3 ligase activity with IRF1 as a substrate. As a negative control, we used a cIAP2 mutant with a point substitution in the RING domain (H574A) that does not have E3 ligase activity 40 . Binding of S1P to that cIAP2 RING-domain mutant was markedly diminished (Fig. 7d) , and that mutant no longer polyubiquitinated IRF1 (Fig. 7e) . In agreement with the molecular modeling data ( Fig. 7c and Supplementary Fig. 3) , and in contrast to -40  4  35  30  25  20  15  10  5  CXCL10 (fold)   40  200  35  30  25  20  15 Figure 7 S1P directly binds to cIAP2 and promotes ubiquitination of IRF1. (a) Liquid chromatography-electrospray ionization-tandem mass spectrometry of bound S1P in lysates of HEK293 cells transfected to express Flag-tagged IRF1 or HA-tagged cIAP2, followed by immunoprecipitation with anti-Flag, anti-HA or control IgG (presented as femtomoles of S1P). (b) Binding of 32 P-labeled S1P in lysates of HEK293 cells transfected to express empty vector (EV) or HA-tagged cIAP2 (key), followed by incubation of lysates for 10 min with 0.1 nM 32 P-labeled S1P alone (Ctrl) or together with 1 µM unlabeled competitor (S1P, DHS1P, Sph or LPA) and then immunoprecipitation with anti-HA agarose beads. (c) Docking of S1P into the pocket of the RING domain of cIAP2; in the surface contour of the binding site with S1P, colors indicate electrostatic potential (blue, positive; white, neutral; red, negative). Estimated inhibition constant values 45 : 3.72 × 10 −6 (S1P) and 19.72 × 10 −6 (DHS1P). (d) Spectrometry analysis (top) as in a of bound S1P in lysates of HEK293 transfected to express empty vector or hemagglutinin-tagged wild-type cIAP2 (cIAP2) or mutant cIAP2 with a point substitution (H574A) in the RING domain (cIAP2(H574A)) or with the substitutions T594A, I595A and K596A (cIAP2(AAA)), followed by immunoprecipitation with anti-HA. HC, IgG heavy chain. Input (bottom), samples without immunoprecipitation. (e) In vitro ubiquitination assay of purified Flag-tagged IRF1, the HA-tagged wildtype and mutant cIAP constructs in d, and ATP, E1, UbcH5a and ubiquitin in the presence or absence of 100 nM S1P, detected by immunoblot analysis with anti-IRF1. *P < 0.01 and **P < 0.001 (one-way ANOVA). Data are representative of three experiments (average and s.d. in a,b,e).
wild-type cIAP2, mutant cIAP2 with the substitutions T594A, I595A and K596A did not bind S1P efficiently (Fig. 7d) and lost its in vitro E3 ligase activity toward IRF1 (Fig. 7e) . Collectively, our studies identified a previously undescribed signaling cascade activated by IL-1 (Supplementary Fig. 4 ) that led to the activation of newly synthesized IRF1 and subsequent induction of IRF1-dependent genes. Activation of IRF1 required its K63-linked polyubiquitination mediated by cIAP2 and depended on the production of S1P by SphK1.
DISCUSSION
Considerably less is known about the function and regulation of IRF1 than about that of IRF3 and IRF7. In addition to the already known functions of IRF1, TNF-activated IRF1 has been shown to induce the expression of several chemokines and low expression of IFN-β that subsequently activates the ISGF3 complex and sustains the expression of TNF-induced chemokines 17 . It has also been demonstrated that the recruitment of monocytes by endothelial cells requires the activation of IRF1 by the TNF receptor TNFR2 (ref. 20) . Here we demonstrated that IRF1 was also required for IL-1-induced expression of CXCL10 and CCL5 in astrocytes and MEFs in vitro and in mice in vivo. Furthermore, IRF1 was required for turpentine-induced, IL-1-dependent expression of CXCL10 and CCL5 and subsequent recruitment of mononuclear cells into sites of sterile inflammation. The importance of local chemokine production is further supported by a report that Irf1 −/− mice with wild-type bone marrow have milder clinical signs and shorter disease duration for experimental autoimmune encephalomyelitis than do wild-type mice 41 . Therefore, our findings may in part explain the diminished susceptibility of Irf1 −/− mice to autoimmune diseases, such as collagen-induced arthritis and experimental autoimmune encephalomyelitis, that are dependent in part on IL-1.
Transcriptional induction of IRF1 and stabilization of IRF1 protein are probably not sufficient for the activation of IRF1-dependent genes. The IFN-γ-induced expression of CXCL10 requires further activation of IRF1, possibly by phosphorylation 25 . Indeed, IKKβ is needed for the IRF1-dependent expression of CXCL10 in response to IFN-γ 25 , whereas activation of IRF1 after signaling via TLR7 and TLR9 requires IKKα, which immunoprecipitates together with IRF1 and phosphorylates IRF1 in vitro 14 . Analogously, other IRFs are activated via phosphorylation, with phosphorylation of IRF7 requiring prior K63-linked polyubiquitination by TRAF6 (ref. 23) . Although the stability of IRF1 is controlled by its K48-linked polyubiquitination that targets it for proteasomal degradation 42 , we have now presented evidence that IRF1 also underwent K63-linked polyubiquitination in response to IL-1. K63-linked polyubiquitination of IRF1 occurs in its DNA-binding domain and thus may counteract constitutive K48linked polyubiquitination, which also targets residues in the DNAbinding domain of IRF1 (ref. 42 ). IFN-γ-induced IRF1 is known to form a complex with and is activated by MyD88 after stimulation of the TLR, by a process referred to as 'MyD88-dependent licensing' 24 . Thus, our finding that activation of the IL-1R complex, which uses MyD88 as a signaling adaptor, led to K63-linked polyubiquitination of IRF1 suggests that MyD88-dependent licensing probably involves K63-linked polyubiquitination. However, we found that TRAF6, an E3 ubiquitin ligase that orchestrates activation of NF-κB and MAPK in response to IL-1 (ref. 43) , did not mediate polyubiquitination of IRF1. In response to IL-1, cIAP2 was recruited to TRAF6 and became polyubiquitinated, which suggested cIAP2 activation. The closely related cIAP1 and cIAP2 are redundant for many of their known functions; nevertheless, they also have unique functions, such as cIAP1-coordinated activation of NF-κB in response to DNA damage 41 . K63-linked polyubiquitination of IRF1 was unambiguously mediated by cIAP2 but not by cIAP1. As IL-1-induced polyubiquitination of IRF1 and activation of IRF1-dependent genes was almost completely abrogated in Birc3 −/− (cIAP2-deficient) MEFs, cIAP2 probably has a critical and nonredundant role in the activation of IRF1-dependent responses. That was further supported by the finding that cIAP2 mutants that lacked E3 ubiquitin ligase activity or S1P binding failed to polyubiquitinate IRF1 in vitro. S1P was also required for K63-linked polyubiquitination of IRF1 by cIAP2, which highlights another previously unknown direct intracellular target of the signaling lipid S1P. Intracellular S1P has been shown to bind directly to several intracellular targets and specifically regulate their activity 44 . We detected efficient and specific binding of S1P to cIAP2. Furthermore, molecular modeling of the binding of S1P to cIAP2 identified potentially important amino acids and allowed the generation of a cIAP2 mutant that neither bound S1P nor polyubiquitinated IRF1 in vitro, which suggested that S1P serves as a true obligatory cofactor for the E3 ligase activity of cIAP2. Since SphK1 was activated in response to IL-1 and also immunoprecipitated together with cIAP2, S1P is probably generated at the time cIAP2 is activated. That mechanism is similar to the one observed after stimulation with TNF, in which SphK1 is also activated and forms a complex with TRAF2 (ref. 34) . The importance of SphK1 for IL-1-induced, IRF1-dependent gene expression was further supported by our finding that pharmacological inhibition of SphK1 activity or genetic deletion of SphK1 diminished the expression of IRF1-dependent genes in vitro and in vivo. Our data collectively suggest that in contrast to TLRs, which efficiently recruit mononuclear cells of the immune system to sites of infection by IRF3-and IRF7-dependent activation of chemokine expression, the recruitment of such cells to sites of sterile inflammation is coordinated by IL-1R-mediated activation of IRF1. As IRF1 affects the pathogenesis of autoimmune diseases 22 , targeting of this previously unrecognized IL-1-induced cascade may be clinically important in the future.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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Molecular modeling of cIAP2 with S1P. The molecular docking program AutoDock 4.2 was used for automated molecular docking simulations 45 . PDBQT files were created for both ligands and cIAP2 with the Gasteiger charge assigned, and the AutoGrid algorithm was used for precalculation of the atomic affinity grid used in the docking simulation. Complexes were selected on the basis of criteria of interacting energy combined with geometrical matching quality. Figures were generated with the PyMOL molecular graphics system. The program LIGPLOT (version 4.4.2) 50 was used for delineation of the detailed interactions between ligands and cIAP2. An interaction was considered a hydrophobic interaction if the distance of two hydrophobic atoms between ligand and the protein residue was less than 3.9 Å and was considered a hydrogen bond if it was between a listed donor and acceptor and the angles and distances formed by the atoms surrounding the hydrogen bond lay within the default criteria.
Statistical analysis.
All experiments were repeated at least three times, except as indicated in figure legends, with consistent results. Samples were not excluded. Data are presented as mean and s.d. or s.e.m (as noted in figure legends). For mouse studies, four to seven randomly chosen mice were used per experimental group. Most of the animal experiments were done by researchers 'blinded' to sample identity, whereas most in vitro experiments were not. SPSS Statistics 21 software was used for statistical analyses. A Bonferroni post-hoc test was used for one-way ANOVA comparisons, with a P value of <0.05 being considered statistically significant. Additionally, independent sample Student's t-test also was used for data analysis.
